2025
High Phosphate and Low Protein Mediate Arterial and Cutaneous Vascular Calcification in CKD Mice.
Jin Y, Cao F, Xie Y, Davis S, Dong G, Nigwekar S, Hansen J, Guzman R, Cai Y. High Phosphate and Low Protein Mediate Arterial and Cutaneous Vascular Calcification in CKD Mice. Journal Of The American Society Of Nephrology 2025 PMID: 40960881, PMCID: PMC12448113, DOI: 10.1681/asn.0000000875.Peer-Reviewed Original ResearchChronic kidney diseaseChronic kidney disease miceCutaneous vascular calcificationArteriolar calcificationVascular calcificationP38 MAPK signalingMedial arterial calcificationPharmacological inhibition of p38 MAPK signalingArtery calcificationLow-protein dietPharmacological inhibitionMedial arteryInhibition of p38 MAPK signalingCKD mouse modelMolecular pathwaysMAPK signalingExperimental CKD modelsPharmacological inhibitor SB203580Kidney impairmentAlizarin red stainingNephrectomy miceSignaling in vivoVascular complicationsKidney dysfunctionTreatment strategiesQualitative Analysis and Comparison of Externally Led Patient-Focused Drug Development (EL-PFDD) Concepts for Autosomal Recessive Polycystic Kidney Disease (ARPKD) Against SONG Initiatives
Soyfer B, Fedeles S, Ruyle W, Hoover E, Liebau M, Hartung E, Dell K, Guay-Woodford L, Perrone R, Oberdhan D. Qualitative Analysis and Comparison of Externally Led Patient-Focused Drug Development (EL-PFDD) Concepts for Autosomal Recessive Polycystic Kidney Disease (ARPKD) Against SONG Initiatives. Kidney Medicine 2025, 101110. DOI: 10.1016/j.xkme.2025.101110.Peer-Reviewed Original ResearchAutosomal recessive polycystic kidney diseasePatient-focused drug developmentRecessive polycystic kidney diseaseQuality of lifePolycystic kidney diseasePatient perspectiveARPKD patientsKidney diseaseProgressive kidney dysfunctionEarly-onset diseaseClinical trial designDrug developmentRenal manifestationsOutcome measuresLiver complicationsHepatic complicationsStandardized outcomesNovel therapiesKidney dysfunctionPathogenic variantsPKHD1 geneDisease burdenDisease managementDisease progressionClinical heterogeneity
2024
Mechanistic Differences between Torsemide and Furosemide
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024, 36: 99-107. PMID: 39196651, PMCID: PMC11706557, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weightImpact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF
Martens P, Greene S, Mentz R, Li S, Wojdyla D, Kapelios C, Mullens W, Hall M, Ketema F, Kim D, Eisenstein E, Anstrom K, Fang J, Pitt B, Velazquez E, Tang W. Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF. European Journal Of Heart Failure 2024, 26: 1242-1250. PMID: 38558520, DOI: 10.1002/ejhf.3207.Peer-Reviewed Original ResearchEffect of torsemideBaseline renal functionRenal functionHeart failureKCCQ-CSSRandomized patientsKansas City Cardiomyopathy Questionnaire clinical summary scoreSpectrum of renal functionBaseline kidney dysfunctionCategories of estimated glomerular filtration rateTrial randomized patientsClinical summary scoreAdverse clinical outcomesGlomerular filtration rateAll-Cause MortalityTreatment effect modificationModify treatment effectsPost Hoc AnalysisPatient-reported outcomesDiuretic efficacyBaseline eGFRNo significant differenceClinical outcomesKidney dysfunctionFiltration rateHeterozygous mutations in factor H aggravate pathological damage in a stable IgA deposition model induced by Lactobacillus casei cell wall extract
Li J, Dong Y, Chen F, Yang H, Chen P, Li H, Shi S, Zhou X, Zhu L, Zhang Y, Liu L, Xie X, Yu F, Jin J, Lv J, Zhang H. Heterozygous mutations in factor H aggravate pathological damage in a stable IgA deposition model induced by Lactobacillus casei cell wall extract. Frontiers In Immunology 2024, 15: 1368322. PMID: 38558821, PMCID: PMC10978756, DOI: 10.3389/fimmu.2024.1368322.Peer-Reviewed Original ResearchCell wall extractsLactobacillus casei cell wall extractBiomarkers of kidney dysfunctionComplement activationFactor H mutationSeverity of glomerular lesionsPositive rate of IgAMild kidney damageDecline of kidney functionPathogenesis of IgA nephropathyProduction of IgA.Wall extractsGlomerular IgA depositionPathogenesis of IgANWild type controlsComplement overactivationElevated IgAElevated biomarkersHeterozygous mutationsC57BL/6 miceIgA-IgGKidney dysfunctionAlternative pathwayComplement inhibitorsIgA nephropathy
2023
Trends of national and sub-national burden attributed to kidney dysfunction risk factor in Iran: 1990-2019
Nejadghaderi S, Moghaddam S, Keykhaei M, Shobeiri P, Rezaei N, Rezaei N, Collaborators G, Naghavi M, Larijani B, Farzadfar F, Nejadghader S, Moghaddam S, Keykhaei M, Shobeiri P, Rezaei N, Rezaei N, Abdollahi A, Ahmadi A, Ahmadi S, Alatab S, Arabloo J, Arjomandzadegan M, Athari S, Azadnajafabad S, Azangou-Khyavy M, Baghcheghi N, Bagherieh S, Barati S, Dehghan A, Fatehizadeh A, Ghadirian F, Gholamalizadeh M, Gholami A, Gohari K, Hassankhani H, Jokar M, khorashadizadeh F, Kompani F, Koohestani H, Mahjoub S, Mahmoodpoor A, Rad E, Mobayen M, Mohammadi E, Moradi Y, Morovatdar N, Noori M, Okati-Aliabad H, Pourali G, Rafferty Q, Rashedi S, Rashidi M, Rashidi M, Sahebkar A, Shorofi S, Tabatabaei S, Taheri M, Taherkhani A, Zahir M, Zangiabadian M, Zare I, Naghavi M, Larijani B, Farzadfar F. Trends of national and sub-national burden attributed to kidney dysfunction risk factor in Iran: 1990-2019. Frontiers In Endocrinology 2023, 14: 1115833. PMID: 36923218, PMCID: PMC10010168, DOI: 10.3389/fendo.2023.1115833.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsDisability-adjusted life year ratesGlobal Burden of DiseaseRisk factorsAge-standardized death ratesAge-standardized disability-adjusted life yearsSub-national burdenComparative risk assessment frameworkAge-standardized DALY rateAge-standardized deathDeath rateBurden of diseaseKidney dysfunctionYears of lifeSocio-Demographic Index regionsDALY ratesPeripheral arterial diseasePrevention programsProvince of TehranGlobal burdenIschemic heart diseaseLife yearsPositive associationCardiovascular diseasePrevention of kidney dysfunctionGlobal burden of gout in 1990–2019: A systematic analysis of the Global Burden of Disease study 2019
Jeong Y, Park S, Yon D, Lee S, Tizaoui K, Koyanagi A, Jacob L, Kostev K, Dragioti E, Radua J, Stickley A, Oh H, Shin J, Smith L. Global burden of gout in 1990–2019: A systematic analysis of the Global Burden of Disease study 2019. European Journal Of Clinical Investigation 2023, 53: e13937. PMID: 36511834, DOI: 10.1111/eci.13937.Peer-Reviewed Original ResearchConceptsGlobal Burden of DiseaseGlobal burden of goutBurden of goutSociodemographic indexGlobal burdenRisk factorsKidney dysfunctionGlobal Burden of Disease StudyAge-standardized prevalence rateBurden of Disease StudyDisease burden of goutHigher age-standardized prevalenceAge-standardized prevalenceAge-standardized ratesHigher Body Mass IndexHigh-income North AmericaHigh sociodemographic indexGlobal prevalence of goutYear of diagnosisBurden of diseaseBody mass indexPrevalence of goutGeographic risk factorsSociodemographic statusAssociated with sex
2022
The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Kanbay M, Copur S, Siriopol D, Yildiz A, Berkkan M, Popa R, Hasbal N, Ortiz A, Perazella M. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Clinical Kidney Journal 2022, 16: 817-826. PMID: 37151409, PMCID: PMC10157786, DOI: 10.1093/ckj/sfac194.Peer-Reviewed Original ResearchAcute kidney injuryImmune checkpoint inhibitorsEffect of AKICheckpoint inhibitorsCancer patientsKidney injuryDevelopment of AKISystematic reviewImmune checkpoint inhibitor therapySevere acute kidney injuryPersistent kidney dysfunctionSevere AKI patientsCheckpoint inhibitor therapyRisk of deathNon-randomized studiesCochrane Library databasesRisk of mortalityNovel therapeutic approachesWeb of ScienceAKI patientsICPI treatmentCause mortalityInhibitor therapyKidney dysfunctionMortality outcomesImproving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials
Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD. Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. Kidney International Reports 2022, 7: 1939-1950. PMID: 36090489, PMCID: PMC9458993, DOI: 10.1016/j.ekir.2022.06.005.Peer-Reviewed Original ResearchChronic kidney diseaseEnd-stage kidney diseaseSevere kidney dysfunctionKidney diseaseKidney dysfunctionAdvanced kidney diseaseOptimal clinical careCancer drug trialsNumber of patientsNarrow therapeutic indexInitial clinical studiesKidney replacement treatmentPreregistration studiesKidney functionCancer careReplacement treatmentCancer trialsClinical trialsEffective dosingClinical studiesTreatment decisionsDrug trialsBeneficial drugsClinical carePatientsThe removal of race from kidney function estimation: Key points for primary providers
Aklilu A, Delgado C. The removal of race from kidney function estimation: Key points for primary providers. Journal Of The National Medical Association 2022, 114: s25-s33. PMID: 35595580, DOI: 10.1016/j.jnma.2022.05.008.Peer-Reviewed Original ResearchConceptsKidney functionKidney function estimationChronic kidney diseasePrimary care providersGlomerular filtration rate estimationKidney dysfunctionKidney diseaseRisk factorsCare providersNephrology societiesSocial determinantsPrimary providersEarly detectionInclusion of raceTask ForceMedical algorithmsRecent recognitionWidespread implementationGFRProvidersDysfunctionRaceDiseaseProgressionPost-acute sequelae of SARS-CoV-2 infection: relationship of central nervous system manifestations with physical disability and systemic inflammation
Busatto G, de Araujo A, Castaldelli-Maia J, Damiano R, Imamura M, Guedes B, de Rezende Pinna F, Sawamura M, Mancini M, da Silva K, Garcia M, Sumita N, Brunoni A, da Silva Duarte A, Burdmann E, Kallas E, Cerri G, Nitrini R, Bento R, Rocha V, de Souza H, Miguel E, de Carvalho C, Forlenza O, Batistella L. Post-acute sequelae of SARS-CoV-2 infection: relationship of central nervous system manifestations with physical disability and systemic inflammation. Psychological Medicine 2022, 52: 2387-2398. PMID: 35521752, PMCID: PMC9151630, DOI: 10.1017/s0033291722001374.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionPost-acute sequelaeC-reactive proteinSystemic inflammationBlood levelsPhysical disabilityD-dimer blood levelsCentral nervous system manifestationsPersistent physical disabilityPersistent systemic inflammationNervous system manifestationsSevere COVID-19Cognitive manifestationsPoor physical performanceElevated blood levelsCoronavirus disease 2019Pattern of symptomsDifferent organ systemsExploratory factor analysisSame followSystem manifestationsD-dimerClinical manifestationsKidney dysfunctionPerson visits
2018
Kidney Dysfunction After Vascularized Composite Allotransplantation
Krezdorn N, Tasigiorgos S, Wo L, Lopdrup R, Turk M, Kiwanuka H, Ahmed S, Petruzzo P, Bueno E, Pomahac B, Riella L. Kidney Dysfunction After Vascularized Composite Allotransplantation. Transplantation Direct 2018, 4: e362. PMID: 30046652, PMCID: PMC6056276, DOI: 10.1097/txd.0000000000000795.Peer-Reviewed Original ResearchGlomerular filtration rateKidney dysfunctionCreatinine levelsTrough levelsRisk factorsCalcineurin inhibitor trough levelsNonrenal solid organ transplantsLong-term patient outcomesFirst year posttransplantSuccessful midterm outcomesRenal risk factorsSolid organ transplantsAlternative immunosuppressive agentsComposite tissue transplantationAcute rejectionVCA patientsYear posttransplantMidterm outcomesRenal dysfunctionIR patientsKidney complicationsRenal functionMajor complicationsImmunosuppressive agentsKidney parametersGadolinium-Based Contrast Agent-Related Toxicities
Pasquini L, Napolitano A, Visconti E, Longo D, Romano A, Tomà P, Espagnet M. Gadolinium-Based Contrast Agent-Related Toxicities. CNS Drugs 2018, 32: 229-240. PMID: 29508245, DOI: 10.1007/s40263-018-0500-1.Peer-Reviewed Original ResearchConceptsGadolinium-based contrast agentsGadolinium-based contrast agent administrationContrast agent administrationAgent administrationSystemic disease of unknown etiologyPre-contrast T1-weighted imagesDisease of unknown etiologyNormal renal functionContrast agent accumulationContrast agentsNephrogenic systemic fibrosisT1-weighted imagesSignal intensity changesRenal functionUnknown etiologyClinical consequencesKidney dysfunctionSystemic fibrosisAgent accumulationContrast agent distributionPathological samplesBrain accumulationPharmacokinetic propertiesPatientsPhysiological changes
2017
Hepatic vein pressure predicts GFR in cirrhotic patients with hemodynamic kidney dysfunction
Desai N, Neugarten J, Dominguez M, Golestaneh L. Hepatic vein pressure predicts GFR in cirrhotic patients with hemodynamic kidney dysfunction. Physiological Reports 2017, 5: e13301. PMID: 28611152, PMCID: PMC5471440, DOI: 10.14814/phy2.13301.Peer-Reviewed Original ResearchConceptsHepatic vein pressureTransjugular intrahepatic portosystemic shuntEnd-stage renal diseaseParenchymal kidney diseaseChronic kidney diseaseVein pressureRenal diseaseKidney diseaseCirrhotic patientsUltrasound evidenceCohort of cirrhotic patientsLiver diseaseIntrahepatic portosystemic shuntIntra-abdominal hypertensionPercentage of patientsAssociated with eGFRIntra-abdominal pressureChart reviewLiver failureKidney dysfunctionPortosystemic shuntMultivariate linear regressionEGFRPatientsProteinuriaEffect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial
Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O’Connor T, Velasco MR, Weckstein D, O’Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 2017, 317: 48-58. PMID: 28030702, PMCID: PMC5321662, DOI: 10.1001/jama.2016.19425.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBone and BonesBone Density Conservation AgentsBone NeoplasmsBreast NeoplasmsDiphosphonatesDrug Administration ScheduleFemaleHumansImidazolesMaleMiddle AgedMultiple MyelomaPain MeasurementProstatic NeoplasmsSample SizeSpinal Cord CompressionSpinal FracturesZoledronic AcidConceptsSkeletal morbidity rateProportion of patientsDosing groupZoledronic acidBone metastasesMultiple myelomaProstate cancerBreast cancerSkeletal eventsKidney dysfunctionBone turnoverMorbidity rateClinical trialsEastern Cooperative Oncology Group performance statusOpen-label clinical trialEnd pointIncidence of osteonecrosisYear of randomizationPerformance status scorePrimary end pointSecondary end pointsBrief Pain InventoryMetastatic breast cancerMetastatic prostate cancerAcceptable treatment option
2014
β-catenin and its alteration in an experimental model of diabetic nephropathy.
Park S, Ahn E, Ha T, Shin J. β-catenin and its alteration in an experimental model of diabetic nephropathy. Iranian Journal Of Kidney Diseases 2014, 8: 299-309. PMID: 25001136.Peer-Reviewed Original ResearchConceptsAdvanced glycation endproductsGlomerular epithelial cellsBeta-CateninPresence of advanced glycation endproductsExperimental models of diabetic nephropathyDevelopment of kidney dysfunctionEpithelial cellsRat glomerular epithelial cellsModel of diabetic nephropathyRedistribution of beta-cateninBeta-catenin stainingBeta-catenin proteinBeta-catenin mRNAReverse transcription-polymerase chain reactionCadherin protein complexPodocytes in vitroTranscription-polymerase chain reactionNormal glucose conditionsWestern blot analysisNo significant changesKidney dysfunctionBeta-catenin productionDiabetic nephropathyB-cateninImmunofluorescence staining
2012
Temporal Trends and Predictors in the Use of Aldosterone Antagonists Post-Acute Myocardial Infarction
Rassi A, Cavender M, Fonarow G, Cannon C, Hernandez A, Peterson E, Peacock W, Laskey W, Rosas S, Zhao X, Schwamm L, Bhatt D. Temporal Trends and Predictors in the Use of Aldosterone Antagonists Post-Acute Myocardial Infarction. Journal Of The American College Of Cardiology 2012, 61: 35-40. PMID: 23137936, DOI: 10.1016/j.jacc.2012.08.1019.Peer-Reviewed Original ResearchMeSH KeywordsAgedDiabetes MellitusDrug PrescriptionsDrug UtilizationFemaleGuideline AdherenceHeart FailureHospital Bed CapacityHumansKidney DiseasesMaleMineralocorticoid Receptor AntagonistsMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationPatient DischargePractice Guidelines as TopicRegistriesSmokingStroke VolumeUnited StatesConceptsPost-acute myocardial infarctionAldosterone antagonist useAldosterone antagonist therapyAldosterone antagonistsEjection fractionAntagonist useEligible patientsAntagonist therapyHospital dischargeHeart failureMyocardial infarctionActual prescribing patternsGuideline-based therapyAbsence of contraindicationsHistory of diabetesPost-AMI patientsHigher ejection fractionAmerican Heart AssociationLarger hospital sizeCoronary revascularizationPrescribing patternsAMI patientsKidney dysfunctionPost-AMITobacco abuse
2009
Increased Mortality among Survivors of Myocardial Infarction with Kidney Dysfunction: the Contribution of Gaps in the use of Guideline-Based Therapies
Peterson PN, Ambardekar AV, Jones PG, Krumholz HM, Schelbert E, Spertus JA, Rumsfeld JS, Masoudi FA. Increased Mortality among Survivors of Myocardial Infarction with Kidney Dysfunction: the Contribution of Gaps in the use of Guideline-Based Therapies. BMC Cardiovascular Disorders 2009, 9: 29. PMID: 19586550, PMCID: PMC2716301, DOI: 10.1186/1471-2261-9-29.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedFemaleGlomerular Filtration RateHumansKaplan-Meier EstimateKidney DiseasesMaleMiddle AgedMyocardial InfarctionPractice Guidelines as TopicProportional Hazards ModelsProspective StudiesRegistriesRisk AssessmentSeverity of Illness IndexSurvivorsTime FactorsTreatment OutcomeUnited StatesConceptsGlomerular filtration rateAcute myocardial infarctionGuideline-based medical therapyGuideline-based therapyMedical therapyKidney dysfunctionMyocardial infarctionUse of guidelinesEligible patientsRenal dysfunctionHazard ratioCox regressionPathophysiological abnormalitiesClinical variablesKidney diseaseFiltration rateNovel therapiesUS CentersHigh mortalityPatientsTherapyFurther adjustmentMortalityDysfunctionTreatment factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply